Isofol Medical: First patient enrolled in phase III trial
Isofol Medical took a major step forward today, announcing that the first patient has been enrolled in the phase III trial AGENT, studying arfolitixorin in metastatic colorectal cancer (mCRC). We believe that the share price reaction was too modest and argue that the current share price reflects a valuation far from the fundamental value. We will return with an updated analysis shortly.